Literature DB >> 9894407

[Cystic fibrosis].

N Høiby1, C Koch, B Frederiksen.   

Abstract

Cystic fibrosis (CF), the most common life-threatening autosomal recessive disorder in Causcasian populations, is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on chromosome 7, which encodes a protein that functions as a chloride channel in the apical membrane of epithelial cells. The clinical manifestations comprise recurrent and chronic bronchopulmonary infections, pancreatic insufficiency, and hidrotic salt depletion. Such complications as diabetes, cirrhosis, and respiratory insufficiency develop, resulting in death in the absence of lung transplantation. Treatment is aggressive and comprehensive from the time of diagnosis. Early and intensive treatment of bacterial colonisation and lung infection is correlated with improved prognosis, and monthly follow-up at a CF Centre is mandatory. Mean survival among CF patients at the Danish CF Centre i Copenhagen is more than 40 years. Clinical trials of gene therapy are under way, but results to date have been disappointing.

Entities:  

Mesh:

Year:  1998        PMID: 9894407

Source DB:  PubMed          Journal:  Nord Med        ISSN: 0029-1420


  2 in total

1.  Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation.

Authors:  Jennifer M Bomberger; Kenneth H Ely; Naveen Bangia; Siying Ye; Kathy A Green; William R Green; Richard I Enelow; Bruce A Stanton
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

2.  A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system.

Authors:  Jennifer M Bomberger; Siying Ye; Daniel P Maceachran; Katja Koeppen; Roxanna L Barnaby; George A O'Toole; Bruce A Stanton
Journal:  PLoS Pathog       Date:  2011-03-24       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.